WuXi XDC Cayman Revenue

In the year 2025, WuXi XDC Cayman had annual revenue of 5.94B CNY with 46.69% growth. WuXi XDC Cayman had revenue of 3.24B in the half year ending December 31, 2025, with 186.93% growth.

Revenue

5.94B CNY

Revenue Growth

+46.69%

P/S Ratio

11.29

Revenue / Employee

2.23M CNY

Employees

2,662

Market Cap

74.68B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	5.94B	1.89B	46.69%
Dec 31, 2024	4.05B	1.93B	90.80%
Dec 31, 2023	2.12B	1.13B	114.44%
Dec 31, 2022	990.42M	679.29M	218.33%
Dec 31, 2021	311.13M	214.78M	222.91%
Dec 31, 2020	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Guanze Medical Information Industry (Holding)	98.42M
Adicon Holdings	2.94B
Mega Genomics	275.03M
Kindstar Globalgene Technology	1.04B
China Biotech Services Holdings	73.50M
Biosino Bio-Technology and Science Incorporation	205.08M
Yunkang Group	669.23M
King International Investment	77.50M

Revenue Rankings

WuXi XDC Cayman News

22 days ago - Akari Therapeutics Announces Strategic Partnership With WuXi XDC - Nasdaq
5 weeks ago - WuXi XDC Cayman Earnings Call Transcript: H2 2025 - Transcripts
6 weeks ago - US reshoring drive casts shadow over China’s contract drug makers: analyst - South China Morning Post

More News